We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov

Exit Notice

You are about to leave ClinicalTrials.gov and go to: Depth of response to isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: Interim analysis of the GMMG-CONCEPT trial. URL: https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.8508

Click on the link to continue or return to ClinicalTrials.gov Home